4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study
1. FDMT shares up 20.6% after positive Spectra trial results. 2. 4D-150 demonstrated significant improvement in visual acuity for DME patients. 3. The drug shows 78% reduction in treatment burden compared to current standards. 4. 4D-150 was well-tolerated with no significant safety concerns reported. 5. Marketing authorization may soon follow due to regulatory agreement.